Protection against Doxorubicin-Induced Cytotoxicity by Geniposide Involves AMPKα Signaling Pathway

Area of Science:

• Cardiovascular Pharmacology
• Molecular Cardiology
• Toxicology

Background:

• Doxorubicin (DOX) is a widely used chemotherapy agent, but its clinical application is limited by cardiotoxicity.
• Oxidative stress and cardiomyocyte apoptosis are key mechanisms underlying DOX-induced cardiotoxicity.
• Geniposide (GE), a traditional Chinese medicine component, has shown potential in mitigating oxidative stress and apoptosis.

Purpose of the Study:

• To investigate the protective effects of geniposide (GE) against doxorubicin- (DOX-) induced cardiotoxicity.
• To elucidate the underlying molecular mechanisms, particularly the role of AMP-activated protein kinase alpha (AMPKα).

Main Methods:

• A mouse model of doxorubicin-induced cardiomyopathy was established.
• Mice were treated with geniposide (GE) orally for 10 days.
• Morphological examination, biochemical analysis, and in vitro studies using H9C2 cells were performed.
• The role of AMP-activated protein kinase alpha (AMPKα) was assessed by inhibiting its activity.

Main Results:

• Geniposide (GE) treatment alleviated heart dysfunction and reduced cardiac oxidative stress and cardiomyocyte loss induced by doxorubicin (DOX) in vivo and in vitro.
• GE activated AMP-activated protein kinase alpha (AMPKα) in cardiac tissues and cells.
• Inhibition of AMPKα abolished the protective effects of GE against DOX-induced cardiotoxicity.

Conclusions:

• Geniposide (GE) demonstrates significant cardioprotective effects against doxorubicin-induced cardiotoxicity.
• The protective mechanism involves the activation of AMP-activated protein kinase alpha (AMPKα), which mitigates oxidative stress and apoptosis.
• Geniposide (GE) holds therapeutic potential for managing doxorubicin cardiotoxicity.